Intended Use

LGI-Flag™ is a computational software tool that is intended to identify individuals at risk for lower GI disorders that warrant further evaluation. It is based on complete blood count (CBC) patterns mainly related to erythrocyte features, measured and derived from peripheral venous blood specimens. LGI-Flag™ is indicated for use in individuals of the general population, between 50 and 75 years of age, who are not under active GI surveillance.

LGI-Flag™ 3.0 is recommended for use by healthcare systems and their affiliates (such as care providers and population health managers) within their Information Technology (IT) systems. LGI-Flag™ is an adjunct to established clinical guidelines and a referral for further evaluation should be based on the clinical judgment of the care provider.

Web-based clinical intelligence platform, primarily utilized in critical care units to guide clinical decisions. The platform has full interoperability with the Electronic Health Record, and combines all relevant data within the complex critical care environment into one visualization to provide a full picture of a patient and their longitudinal trends. FDA-cleared algorithms continually assess the incoming patient information and provide early warning signs of clinical deterioration to aid care teams with determining interventions and treatment. Automated clinical workflows, customized to each individual ICU, provide care efficiency and positively impact clinical outcomes. 

Published clinical outcomes showing:

• Up to 36% reduction in ICU length of stay
• 41% reduction in ICU readmissions
• 22% reduction in time on ventilation
• 18% reduction in time on vasoactive medication

Commercial stage company with market leading AI clinical decision support platform for bedside and remote monitoring of high acuity patients. Published outcomes and strong ROI; utilized in 40+ hospitals & health systems.

Etiometry provides functionality to seamlessly extend the EHR to be effective for care in high-acuity patient settings (e.g. ICU), including automating clinical workflows, and providing in-depth, longitudinal trends.

Etiometry is the only CDS platform with 4 FDA-cleared risk algorithms and the platform's data collection capabilities have led to a vastly larger number of supporting clinical studies (>150).